Cancer treatment has always been seen as a battle, with the goal being to destroy the tumor as quickly and aggressively as possible. However, research has shown that this approach may actually accelerate the development of dangerous mutations within the tumor. Immuneering Corporation is taking a different approach by focusing on slowing down cancer growth rather than immediately attacking it.
In a recent phase 2 trial, Immuneering tested their MEK inhibitor atebimetinib in combination with chemotherapy and saw promising results. The trial showed a significant increase in overall survival rates for pancreatic cancer patients, marking a major breakthrough in a disease with traditionally low survival rates. This approach aims to control cancer growth and turn it into a chronic, manageable disease rather than seeking a cure.
MEK inhibitors target proteins in the mitogen-activated protein kinase pathway, a crucial pathway in many cancers. While MEK inhibitors have shown success in various cancer types, including melanoma and lung cancer, patients often develop resistance to these drugs over time. Immuneering’s unique dosing strategy involves intermittent high-dose treatment to minimize side effects and keep tumors off balance, preventing the development of drug resistance.
The phase 2 trial results for atebimetinib showed a significant improvement in progression-free survival compared to standard care. Some patients even experienced complete disappearance of tumors, a rare occurrence in pancreatic cancer treatment. These promising results have led Immuneering to consider expanding their drug’s use to other cancer types.
Overall, Immuneering’s approach challenges the traditional mindset of cancer treatment. By focusing on slowing down cancer growth and minimizing side effects, they aim to change the way cancer is treated. Rather than trying to outsmart or kill cancer, the goal is to outpace it and turn it into a manageable condition. This new approach could revolutionize cancer treatment and improve outcomes for patients in the future.
